Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858749 · ClinicalTrials.gov registry record
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 494
- Enrollment target
NCT05858749: Completed study, sponsored by Pfizer.
NCT05858749 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 494 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05858749 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 494 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC. The study includes participants who: * are 18 years old or above and have mRCC * took medicines that use the bodies immunity to fight against cancer as their first choice of treatment * took other medicines after taking the above first choice of treatment This is a study that looks into the data collected through a particular database from selected academic clinical sites participating in this study. The data of interest include: * the length of time between the start of a patient's treatment and the end of treatment * the length of time between the start of treatment and death * physician assessment of a patient's response to treatment We will compare the experiences of people receiving different combinations of treatments and see if there are any differences in the effectiveness of these medicines.
Primary Outcome
Gender Age at time of 1L initiation Race Region indicator (i.e., US vs. ex-US)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2022-06-20 |
| Est. Completion | 2022-11-30 |
What the finished NCT05858749 record still lists
NCT05858749 is an observational study that tracks outcomes without assigning an intervention. The registered 494 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05858749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05858749 about?
NCT05858749 is a clinical study titled "A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).". The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC. The study includes participants who: * are 18 years old or above and have mRCC * took medicines that use the bodies immunity to fight against cancer as ...
What is the current status of trial NCT05858749?
This trial is currently completed. The enrollment target is 494 participants. The study started on 2022-06-20. Estimated completion is 2022-11-30.
Who is sponsoring clinical trial NCT05858749?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI